|
||
Calcimax-K2 Actions |
||
Pharmacology: Calcimax-K2 is the active form of vitamin D3 (cholecalciferol). The natural or endogenous supply of vitamin D in man mainly depends on ultraviolet light for conversion of 7-dehydrocholesterol to vitamin D3 in the skin. Vitamin D3 must be metabolically activated in the liver and the kidney before it is fully active on its target tissues. The initial transformation is catalyzed by a vitamin D3-25-hydroxylase enzyme present in the liver, and the product of this reaction is 25-(OH)D3 (calcifediol). The latter undergoes hydroxylation in the mitochondria of kidney tissue and this reaction is activated by the renal 25-hydroxyvitamin D3-1-α-hydroxylase to produce 1,25-(OH)2D3(Calcimax-K2), the active form of vitamin D3.
The known sites of action of Calcimax-K2 are intestine, bone, kidney and parathyroid gland. Calcimax-K2 is the most active known form of vitamin D3 in stimulating intestinal calcium transport. In acutely uremic rats, Calcimax-K2 has been shown to stimulate intestinal calcium absorption. In bone, Calcimax-K2, in conjunction with parathyroid hormone (PTH), stimulates resorption of calcium; and in the kidney, Calcimax-K2 increases the tubular reabsorption of calcium. In vitro and in vivo studies have shown that Calcimax-K2 directly suppresses secretion and synthesis of PTH. A vitamin D-resistant state may exist in uremic patients because of the failure of the kidney to adequately convert precursors to the active compound, Calcimax-K2.
Calcimax-K2 when administered by bolus injection is rapidly available in the bloodstream. Vitamin D metabolites are known to be transported in blood, bound to specific plasma proteins. The pharmacologic activity of an administered dose of Calcimax-K2 is about 3-5 days. Two metabolic pathways for Calcimax-K2 have been identified, conversion to 1,24,25-(OH)3D3 and to calcitroic acid.
Toxicology: Preclinical Safety Data: Carcinogenesis, Mutagenesis, Impairment of Fertility: Long-term studies in animals have not been performed to evaluate the carcinogenic potential of Calcimax-K2. There was no evidence of mutagenicity as studied by the Ames method. No significant effects of Calcimax-K2 on fertility were reported using oral Calcimax-K2.
It is very important that you use Calcimax-K2 only as directed by your doctor. Do not use more of it, do not use it more often, and do not use it for a longer time than your doctor ordered. To do so may cause unwanted side effects or skin irritation.
Calcimax-K2 should only be used on the skin. Do not get it into your eyes, nose, mouth, or vagina. Do not use it on skin areas that have cuts, scrapes, or burns. Do not apply Calcimax-K2 to your nipple or areola, if you are breastfeeding. If it does get on these areas, rinse it off right away with water.
Calcimax-K2 comes with a patient information leaflet. Read and follow the instructions carefully. Ask your doctor if you have any questions.
To use the ointment:
Do not use cosmetics or other skin care products on the treated areas unless directed to do so by your doctor.
The dose of Calcimax-K2 will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of Calcimax-K2. If your dose is different, do not change it unless your doctor tells you to do so.
The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.
If you miss a dose of Calcimax-K2, apply it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule.
Keep out of the reach of children.
Do not keep outdated medicine or medicine no longer needed.
Ask your healthcare professional how you should dispose of any medicine you do not use.
Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.
Do not freeze or refrigerate the ointment.
Use exactly as prescribed by your doctor. Do not use in larger or smaller amounts or for longer than recommended. Follow the directions on your prescription label.
Calcimax-K2 topical is usually applied once in the morning and once in the evening. Follow your doctor's instructions.
Do not share this medication with other people, even if they have the same symptoms you have.
Wash your hands before and after applying this medicine.
Apply a thin layer of the medication and rub it in completely.
Do not cover treated skin areas unless your doctor has told you to.
Calcimax-K2 topical is for use only on areas of psoriasis. Avoid getting it on healthy skin areas.
Calcimax-K2 topical should not be applied to the face or the vaginal area.
Store at room temperature away from moisture and heat. Do not allow the medicine to freeze.
Calcimax-K2 is the active form of vitamin D3 (cholecalciferol). The natural or endogenous supply of vitamin D in man mainly depends on ultraviolet light for conversion of 7-dehydrocholesterol to vitamin D3 in the skin. Vitamin D3 must be metabolically activated in the liver and the kidney before it is fully active on its target tissues. The initial transformation is catalyzed by a vitamin D3-25-hydroxylase enzyme present in the liver, and the product of this reaction is 25-(OH)D3 (calcifediol). The latter undergoes hydroxylation in the mitochondria of kidney tissue, and this reaction is activated by the renal 25-hydroxyvitamin D3-1-α-hydroxylase to produce 1,25-(OH)2D3 (Calcimax-K2), the active form of vitamin D3.
The known sites of action of Calcimax-K2 are intestine, bone, kidney and parathyroid gland. Calcimax-K2 is the most active known form of vitamin D3 in stimulating intestinal calcium transport. In acutely uremic rats, Calcimax-K2 has been shown to stimulate intestinal calcium absorption. In bone, Calcimax-K2, in conjunction with parathyroid hormone, stimulates resorption of calcium; and in the kidney, Calcimax-K2 increases the tubular reabsorption of calcium. In vitro and in vivo studies have shown that Calcimax-K2 directly suppresses secretion and synthesis of PTH. A vitamin D-resistant state may exist in uremic patients because of the failure of the kidney to adequately convert precursors to the active compound, Calcimax-K2.
Calcimax-K2 when administered by bolus injection is rapidly available in the blood stream. Vitamin D metabolites are known to be transported in blood, bound to specific plasma proteins. The pharmacologic activity of an administered dose of Calcimax-K2 is about 3 to 5 days. Two metabolic pathways for Calcimax-K2 have been identified, conversion to 1,24,25-(OH)3D3 and to calcitroic acid.
Users | % | ||
---|---|---|---|
After food | 2 | 100.0% |
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
|